Cargando…
Intravitreal bevacizumab plus propranolol for neovascular age-related macular degeneration (the BEVALOL study): a phase I clinical trial
BACKGROUND: Given the persistently large public health impact of neovascular age-related macular degeneration (nARMD) despite many years of anti-VEGF therapy as the first-line treatment and the demonstrated ability of b-blockers to reduce neovascularization, a synergistic effect between an anti-VEGF...
Autores principales: | Silva Tavares Neto, José Edísio da, Cyrino, Francyne Veiga Reis, Lucena, Moises Moura, Scott, Ingrid U., Messias, André Márcio Vieira, Jorge, Rodrigo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099020/ https://www.ncbi.nlm.nih.gov/pubmed/37055868 http://dx.doi.org/10.1186/s40942-023-00460-1 |
Ejemplares similares
-
Combined intravitreal dexamethasone and bevacizumab injection for the treatment of persistent diabetic macular edema (DexaBe study): a phase I clinical study
por: Veiga Reis, Francyne, et al.
Publicado: (2023) -
Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration
por: Riazi-Esfahani, Mohammad, et al.
Publicado: (2008) -
Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Non-Age-Related Macular Degeneration
por: Salehipour, Masoud, et al.
Publicado: (2010) -
Is monthly retreatment with intravitreal bevacizumab (Avastin(®)) necessary in neovascular age-related macular degeneration?
por: Ghazi, Nicola G, et al.
Publicado: (2010) -
Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
por: Fang, Kai, et al.
Publicado: (2013)